In vitro activity and efficacy of novel dual PARP-HDAC inhibitors

被引：0
|
作者：
Truong, Sarah
Ghaidi, Fariba
Ramos, Louise
Joshi, Jay
Brown, Dennis
Sankar, Neil
Langlands, John
Bacha, Jeffrey
Shen, Wang
Daugaard, Mads
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2021年 / 20卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-21-P081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P081
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Novel dual inhibitors of LSD1-HDAC for treatment of cancer
    Sivanandhan, Dhanalakshmi
    Rajagopalan, Sridharan
    Nair, Sreekala
    Dewang, Purushottam
    Kumar, Durga Prasanna
    Mulakala, Chandrika
    Mahadevan, Lavanya
    Skariah, Neema
    Kavuru, Venkata Giri
    Kuntrapaku, Damodara
    Sajja, Suchitra
    Zainuddin, Mohammad
    Krishnakumar, V
    Singh, Ritu
    Swarnakumari, V
    Gosu, Ramachandraiah
    Aiyar, Jayashree
    Iyer, Pravin
    Rajagopal, Sriram
    CANCER RESEARCH, 2015, 75
  • [22] Searching for Novel HDAC6/Hsp90 Dual Inhibitors with Anti-Prostate Cancer Activity: In Silico Screening and In Vitro Evaluation
    Pinzi, Luca
    Belluti, Silvia
    Piccinini, Isabella
    Imbriano, Carol
    Rastelli, Giulio
    PHARMACEUTICALS, 2024, 17 (08)
  • [23] Protective effects of novel PARP inhibitors in in vitro and in vivo models of stroke
    Abdelkarim, G
    Gertz, K
    Harms, C
    Katchanov, J
    Dimagl, U
    Jagtap, P
    Endres, M
    Szabo, C
    FASEB JOURNAL, 2001, 15 (05): : A939 - A939
  • [24] Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
    Zuco, Valentina
    De Cesare, Michelandrea
    Cincinelli, Raffaella
    Nannei, Raffaella
    Pisano, Claudio
    Zaffaroni, Nadia
    Zunino, Franco
    PLOS ONE, 2011, 6 (12):
  • [25] Recent Study Dual HDAC/PARP Inhibitor for the Treatment of Tumor
    Lu, Haiying
    Bai, Lan
    Zhou, Yanping
    Lu, Yongping
    Jiang, Zhongliang
    Shi, Jianyou
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2019, 19 (12) : 1041 - 1050
  • [26] Novel PARP inhibitors sensitize human leukemic cells in an endogenous PARP activity dependent manner
    Hegde, Mahesh
    Mantelingu, Kempegowda
    Swarup, Hassan A.
    Pavankumar, Chottanahalli S.
    Qamar, Imteyaz
    Raghavan, Sathees C.
    Rangappa, Kanchugarakoppal S.
    RSC ADVANCES, 2016, 6 (08): : 6308 - 6319
  • [27] EFFICACY OF NOVEL TOPOISOMERASE 1 INHIBITORS AND THEIR SYNERGY WITH PARP INHIBITORS IN A MURINE MODEL FOR OVARIAN CANCER
    Szabova, Ludmila
    Gordon, Melanie
    Matzi, Laetitia
    Pommier, Yves
    Ohler, Zoe Weaver
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 222 - 222
  • [28] Teratogenic Activity of HDAC Inhibitors
    Giavini, Erminio
    Menegola, Elena
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (34) : 5438 - 5442
  • [29] Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
    Shirbhate, Ekta
    Singh, Vaibhav
    Jahoriya, Varsha
    Mishra, Aditya
    Veerasamy, Ravichandran
    Tiwari, Amit K.
    Rajak, Harish
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 263
  • [30] Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors
    Liang, Xuewu
    Liu, Hong
    Zhang, Yingjie
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (15) : 1849 - 1852
12345